Tenecteplase Drug Market Research Report – Forecast to 2027

Global Tenecteplase Drug Market Research Report, by Application (Myocardial Infarction, Stroke, DVT), Dosage(Intravenous Dosage, Intracatheter Instillation ), End-User (Hospitals & Clinics, Surgical Centers, Research Centers) – Global Forecast Till 2027

ID: MRFR/Pharma/4940-HCR | | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Tenecteplase drug is an enzyme derived through recombinant DNA technology from a human cell line. This enzyme is used to treat thrombus (blood clots) it is also called as clot-busting drug. Tenecteplase is a bioengineered variant of the activase drug. The key factor responsible for influencing this market is the increasing cases of deep vein thrombosis, stroke, increase in blood pressure patient. According to the  American Heart Association 2017, report every year almost 790,000 Americans have a heart attack. Coronary artery diseases are increasing day by day due to change in lifestyle. These factors enhance the tenecteplase drug market. However, factors such as the high cost of surgical procedures, allergic reaction, side effects associated with the drug are expected to restrict the market growth during the forecast period.


Segmentation


The global tenecteplase drug market is segmented on the basis of application, dosage and end users.


The Tenecteplase drug market, by application segmented into myocardial infarction, stroke, DVT. The Tenecteplase drug market, by dosage intravenous dosage and intracatheter instillation dosage. Intravenous dosage is sub-segmented into an adult and geriatric and intracatheter instillation dosage is sub-segmented into adult, children, and adolescents weighing 30 kg, infants. On the basis of end-user, it is segmented into hospitals and clinics, surgical centers, research centers. On the basis of region, the global tenecteplase drug market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.


Key players


Some of the key players in the global tenecteplase drug market are Boehringer Ingelheim International GmbH, Genentec Inc., Gennova pharmaceutical, Rewine pharmaceuticals, Hisun USA, Emcure Pharmaceutical, Merck Ltd. and Crunchbase Inc., and others.


Regional Market Summary


Global Tenecteplase Drug Market Share (%), by Region, 2017


Tenecteplase Drug Market Share


Sources: National Cancer Institute, Cancer Research UK, the American Cancer Society, Inc, US Department of Health and Human Services National Institutes of Health


It is estimated that North America dominated the global tenecteplase drug market owing to the increasing innovations in clinical practice, myocardial infection, and access to stroke treatment in this region. According to an article published by CDC in October 2015, report 350,000 to 900,000 cases of Venous thromboembolism (VTE) are estimated every year in the US. This influences the market growth in this region.


Europe stood second largest in the tenecteplase drug market due to increase in the incidents of stroke. According to UK stroke, Organization stroke is the 10th leading cause of death in the world, 34,883 mortality cases of stroke found in the UK in 2015. Due to an increase in hypertension and high blood pressure, the cases of stroke are increasing which can be a major reason for increasing the tenecteplase drug market in this region.


Asia-Pacific was projected to be the fastest growing region for the global tenecteplase drug market in 2017. The market is expected to witness growth owing to the rising prevalence of hypertension, changing lifestyle, and increasing cardiac disease in the population. According, to the Australian Bureau of Statistics 2015, 4.1 million Australians had high blood pressure. Such a high incidence of high blood pressure favors the market growth in this region.


The Middle East and Africa holds the least share of the global tenecteplase drug market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.


Market Segmentation and Key Market Players


Global Tenecteplase Drug Market, by Application



  • Myocardial Infarction

  • Stroke

  • Deep Vein Thrombosis


Global Tenecteplase Drug Market, by Dosage



  • Intravenous dosage

  • Adult

  • Geriatric

  • Intracatheter instillation dosage

  • Adult

  • Children and Adolescents Weighing 30 Kg

  • Infants


Global Tenecteplase Drug Market, by End-User



  • Hospitals and clinics

  • Surgical center

  • Research centers

  • Others


Global Tenecteplase Drug Market, by Region



  • Americas

  • Europe

  • Asia-Pacific

  • Middle East & Africa


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers



Frequently Asked Questions (FAQ) :


Tenecteplase drug market growth would be affected due to high surgical costs, allergic reactions, and side-effects.

The applications included in tenecteplase drug market report are myocardial infarction, stroke, and DVT.

Dosage mentioned in teneteplase drug market is intravenous dosage and intracatheter instillation dosage.

The included end users are hospitals & clinics, surgical centers, and research centers.

The players involved in the tenecteplase drug market are Gennova Pharmaceutical, Boehringer Ingelheim International GmbH, Emcure Pharmaceutical, Merck Ltd. Genentec Inc., Hisun USA, Rewine Pharmaceuticals, and Crunchbase Inc., and others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Tenecteplase Drug Market, by Application

6.1 Introduction

6.2 Myocardial Infarction

6.3 Stroke

6.4 Deep Vein Thrombosis

Chapter 7. Global Tenecteplase Drug Market, by Dosage

7.1 Introduction

7.2 Intravenous dosage

7.2.1 Adult

7.2.2 Geriatric

7.3 Intracatheter instillation dosage

7.3.1 Adult

7.3.2 Children and Adolescents weighting 30kg

7.3.3 Infants


Chapter 8. Global Tenecteplase Drug Market, by End-User

8.1 Introduction

8.2 Hospitals and clinics

8.3 Surgical centers

8.4 Research centers

8.5 Other

Chapter 9. Global Tenecteplase Drug Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Boehringer Ingelheim International GmbH

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 Genentec Inc.,

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Gennova pharmaceutical

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Rewine pharmaceuticals

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Hisun USA

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Emcure Pharmaceutical

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Merck ltd.

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 CrunchBase INC.

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.12 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Global Tenecteplase Drug Market Industry Synopsis, 2020–2027

Table 2 Global Tenecteplase Drug Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Tenecteplase Drug Market, by Region, 2020–2027, (USD Million)

Table 4 Global Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

Table 5 Global Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

Table 6 Global Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

Table 7 North America: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

Table 8 North America: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

Table 9 North America: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

Table 10 US: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

Table 11 US: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

Table 12 US: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

Table 14 Canada: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

Table 15 Canada: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

Table 16 South America: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

Table 17 South America: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

Table 18 South America: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

Table 19 Europe: Tenecteplase Drug Market, Application, 2020–2027, (USD Million)

Table 20 Europe: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

Table 21 Europe: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

Table 22 Western Europe: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

Table 23 Western Europe: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

Table 24 Western Europe: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

Table 25 Eastern Europe: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

Table 26 Eastern Europe: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

Table 27 Eastern Europe: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

Table 28 Asia-Pacific: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

Table 29 Asia-Pacific: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

Table 30 Asia-Pacific: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

Table 31 Middle East & Africa: Tenecteplase Drug Market, by Application, 2020–2027, (USD Million)

Table 32 Middle East & Africa: Tenecteplase Drug Market, by Dosage, 2020–2027, (USD Million)

Table 33 Middle East & Africa: Tenecteplase Drug Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Tenecteplase Drug Market

Figure 3 Market Dynamics for the Global Tenecteplase Drug Market

Figure 4 Global Tenecteplase Drug Market Share, by Application 2020

Figure 6 Global Tenecteplase Drug Market Share, by Dosage, 2020

Figure 6 Global Tenecteplase Drug Market Share, by End-User, 2020

Figure 7 Global Tenecteplase Drug Market Share, by Region, 2020

Figure 8 North America Tenecteplase Drug Market Share, by Country, 2020

Figure 9 Europe Prescribed Health Apps Share, by Country, 2020

Figure 10 Asia-Pacific Tenecteplase Drug Market Share, by Country, 2020

Figure 11 Middle East & Africa Tenecteplase Drug Market Share, by Country, 2020

Figure 12 Global Tenecteplase Drug Market: Company Share Analysis, 2020 (%)

Figure 13 Boehringer Ingelheim International GmbH: Key Financials

Figure 14 Boehringer Ingelheim International GmbH: Segmental Revenue

Figure 15 Boehringer Ingelheim International GmbH: Geographical Revenue

Figure 16 Genentec Inc., Key Financials

Figure 17 Genentec Inc., Segmental Revenue

Figure 18 Genentec Inc., Geographical Revenue

Figure 19 Gennova pharmaceutical: Key Financials

Figure 20 Gennova pharmaceutical: Segmental Revenue

Figure 21 Gennova pharmaceutical: Geographical Revenue

Figure 22 Rewine pharmaceuticals: Key Financials

Figure 23 Rewine pharmaceuticals: Segmental Revenue

Figure 24 Rewine pharmaceuticals: Geographical Revenue

Figure 25 Emcure Pharmaceutical: Key Financials

Figure 26 Emcure Pharmaceutical: Segmental Revenue

Figure 27 Emcure Pharmaceutical: Geographical Revenue

Figure 28 Merck ltd.: Key Financials

Figure 29 Merck ltd.: Segmental Revenue

Figure 30 Merck ltd.: Geographical Revenue

Figure 31 Crunchbase Inc.: Key Financials

Figure 32 Crunchbase Inc.: Segmental Revenue

Figure 33 Crunchbase Inc.: Geographical Revenue